

Sheet 1 of 3

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17109-012001 / 922	Application No. 10/658,834				
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>						Applicant Rene Gantier et al.			
(37 CFR §1.98(b))				Filing Date September 8, 2003		Group Art Unit 1631			
<b>U.S. Patent Documents</b>									
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate		
	AA	2004/0081635	04/29/04	Cummins et al.	424	85.6	10/22/03		
	AB	2007/0172459	07/26/07	Gantier et al.	424	85.5	02/13/07		
	AC	4,462,985	07/31/84	Cummins, Jr.	424	85.6	09/07/82		
	AD	4,497,795	02/05/85	Cummins	424	85.6	12/13/82		
	AE	4,820,514	04/11/89	Cummins	424	85.6	12/30/85		
	AF	4,820,515	04/11/89	Cummins	424	85.6	01/04/85		
	AG	5,017,371	05/21/91	Cummins	424	85.4	01/06/88		
	AH	5,019,382	05/28/91	Cummins, Jr.	424	85.7	01/17/90		
	AI	5,215,741	06/01/93	Young et al.	424	85.6	10/30/90		
	AJ	5,817,307	10/06/98	Cummins	424	85.4	06/07/95		
	AK	5,824,300	10/20/98	Cummins	424	85.7	06/07/95		
	AL	5,830,456	11/03/98	Cummins	424	85.7	09/13/94		
	AM	5,846,526	12/08/98	Cummins	424	85.7	06/07/95		
	AN	5,882,640	03/16/99	Cummins	424	85.7	06/07/95		
	AO	5,910,304	06/08/99	Cummins	424	85.7	04/28/92		
	AP	5,997,858	12/07/99	Tovey et al.	424	85.4	05/09/97		
	AQ	6,207,145	03/27/01	Tovey	424	85.4	05/09/97		
	AR	6,299,872	10/09/01	Albrecht et al.	424	85.7	05/02/00		
	AS	6,346,243	02/12/02	Brod	424	85.4	05/19/99		
	AT	6,361,769	03/26/02	Tovey	424	85.4	05/09/97		
	AU	6,387,365	05/14/02	Albrecht et al.	424	85.4	05/19/95		
	AV	6,461,605	10/08/02	Cutler et al.	424	85.7	03/22/02		
	AW	6,479,258	11/12/02	Short	435	69.1	01/31/00		
	AX	6,482,613	11/19/02	Goeddel et al.	435	69.51	01/19/88		
	AY	6,485,480	11/26/02	Brewitt	604	500	02/07/00		
	AZ	6,884,411	04/26/05	Tarro et al.	424	85.7	01/04/99		
	BA	6,946,125	09/20/05	Rahal	424	85.4	08/23/01		

Examiner Signature	/Elly Gerald Stoica/	Date Considered 11/20/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /EGS/

Sheet 2 of 3

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-012001 / 922	Application No. 10/658,834
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))		Applicant Rene Gantier et al.	
		Filing Date September 8, 2003	Group Art Unit 1631

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes      No
	BB	05/003157	01/13/05	WIPO			
	BC	06/024547	03/09/06	WIPO			

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	BD	Callard and Gearing, <i>The Cytokine Facts Book</i> , Academic Press, San Diego, pgs. 157-158, (1994).
	BE	Fumero, S., "Belerofon: a Long-lasting and Orally Available Interferon Alpha" (Meeting Abstract) <i>Third Annual Optimizing Protein and Antibody Therapeutics, Pioneering New Frontiers</i> (January 10, 2007) <a href="http://www.chi-peptalk.com/06_PTT.asp">http://www.chi-peptalk.com/06_PTT.asp</a>
	BF	Martin, P., "Beyond the Next Generation of Therapeutic proteins," October 2006, <a href="http://www.biotech-online.com/artimg/a20062123243425.PDF">http://www.biotech-online.com/artimg/a20062123243425.PDF</a> (accessed on January 11, 2007) (3 pages).
	BG	Martin, P., "Next Generation Products and Prospects for the Oral Delivery of Proteins" (Meeting Abstract) <i>Fourth Annual Protein Process Development</i> (January 11, 2007). <a href="http://www.chi-peptalk.com/06_Ppd.asp">http://www.chi-peptalk.com/06_Ppd.asp</a>
	BH	Martin, P., "The Market for Therapeutic Proteins: New Business Opportunities" (Meeting Abstract) <i>Second Annual Advancing Protein Therapeutics, Engineering the Next Generation of Proteins for Therapeutics</i> (January 13, 2006). <a href="http://www.chi-peptalk.com/pttn2006.asp">http://www.chi-peptalk.com/pttn2006.asp</a>
	BI	Media Release: "In Vivo Studies Provide Hope for Orally Available Protein Therapeutics" Paris, France and Boston, Massachusetts (USA) April 26, 2006 <a href="http://www.prnewswire.co.uk/cgi/news/release?id=169343">http://www.prnewswire.co.uk/cgi/news/release?id=169343</a> (accessed on January 8, 2007) (3 pages)
	BJ	Media Release: "Nautilus Biotech and Angel Biotechnology Sign Agreement to Manufacture Belerofon(R) (Improved Alpha Interferon) for Phase I Clinical Trials" Paris, France and Northumberland, England December 6, 2004 <a href="http://www.prnewswire.co.uk/cgi/news/release?id=135767">http://www.prnewswire.co.uk/cgi/news/release?id=135767</a> (accessed on January 8, 2007) (2 pages)
	BK	Media Release: "Nautilus Biotech Announces Progress on Belerofon, an Improved IFNalpha With Single Amino Acid Sequence Change, Designed to Reduce Frequency of Injection for Hepatitis C Chronic Infection and Cancer" Paris, France March 23, 2004 <a href="http://www.prnewswire.co.uk/cgi/news/release?id=119794">http://www.prnewswire.co.uk/cgi/news/release?id=119794</a> (accessed on January 8, 2007) (2 pages)
	BL	Media Release: "Nautilus Biotech receives FDA approval for Phase 1 clinical trial in the USA for oral Belerofon®, its long-lasting, Interferon-alpha drug", Paris, France May 14, 2007 <a href="http://www.nautilusbiotech.com/news_100507.html">http://www.nautilusbiotech.com/news_100507.html</a> (accessed on May 18, 2007) (3 pages)

Examiner Signature  /Elly Gerald Stoica/	Date Considered  11/20/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /EGS/

Sheet 3 of 3

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-012001 / 922	Application No. 10/658,834
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))		Applicant Rene Gantier et al.	
		Filing Date September 8, 2003	Group Art Unit 1631

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	BM	Media Release: "Nautilus Biotech: 'Next Generation Biopharmaceuticals (NGB)" Paris, France June 21, 2004 <a href="http://www.prnewswire.co.uk/cgi/news/release?id=125241">http://www.prnewswire.co.uk/cgi/news/release?id=125241</a> (accessed on January 8, 2007) (1 page)
	BN	Media Release: "Nautilus Biotech and HanAll Pharmaceutical Announce License Agreement to Develop Three Nautilus Biotech Products in South Korea," Paris, France, 03/06/07, <a href="http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&amp;STORY=/www/story/03-06-2007/0004540099&amp;EDATE=">http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&amp;STORY=/www/story/03-06-2007/0004540099&amp;EDATE=</a> (accessed on 03/16/07) (3 pages).
	BO	Media Release: "Nautilus Biotech announces IND filing for Belerofon®, its oral, long-lasting, Interferon-alpha drug," Paris, France, 02/27/07, <a href="http://www.nautilusbiotech.com/news_270207.html">http://www.nautilusbiotech.com/news_270207.html</a> (accessed on 03/16/07) (3 pages).
	BP	Media Release: "Nautilus Biotech Announces IND Filing for its Injectable Long-Lasting ·INTERFERON-alpha, BELEROFON(R)" Paris, France October 10, 2006 <a href="http://www.prnewswire.co.uk/cgi/news/release?id=181151">http://www.prnewswire.co.uk/cgi/news/release?id=181151</a> (accessed on January 8, 2007) (2 pages)
	BQ	Media Release: "Nautilus Biotech begins Phase I clinical trial in the USA for subcutaneous Belerofon®, its long-lasting, Interferon-alpha drug," Paris, France, 04/02/07, <a href="http://www.nautilusbiotech.com/news_020407.html">http://www.nautilusbiotech.com/news_020407.html</a> (accessed on 04/09/07) (3 pages).
	BR	Runkel et al., "Differences in activity between $\alpha$ and $\beta$ type I interferons explored by mutational analysis," Journal of Biological Chemistry, 273: 8003-8008, (1998).
	BS	Vega, M., "Improving the Delivery and Pharmacokinetics of Therapeutic Proteins by Increased Resistance to Proteolysis" (Meeting Abstract) <i>Second Annual Advancing Protein Therapeutics, Engineering the Next Generation of Proteins for Therapeutics</i> (January 12, 2006) <a href="http://www.chi-peptalk.com/pttn2006.asp">http://www.chi-peptalk.com/pttn2006.asp</a>
	BT	Vega, M., "Next-Generation Protein Therapeutics for Oral Delivery" (Meeting Abstract) <i>Third Annual Optimizing Protein and Antibody Therapeutics, Pioneering New Frontiers</i> (January 9, 2007) <a href="http://www.chi-peptalk.com/06_PTT.asp">http://www.chi-peptalk.com/06_PTT.asp</a>

Examiner Signature  /Elly Gerald Stoica/	Date Considered  11/20/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /EGS/